摘要
小细胞肺癌是一种侵袭性强、难治疗的肿瘤。在所有肺肿瘤中,小细胞肺癌约占20%。患者通常包括70岁年龄组的重度吸烟者,诊疗期间有如下症状,如胸腔内肿瘤生长症状,远处播散或副肿瘤综合征。一个有用的和功能的分类将小细胞肺癌分为局限性疾病和广泛性疾病。同期化疗是限制性疾病的标准治疗方法,与预防性头颅照射联合使用可提高生存率。铂类药物(顺铂/卡铂加依托泊苷)是广泛的疾病的基石。然而,尽管这种癌症的化疗和辐射敏感性高,几乎所有患者在最初两年内复发,预后极差。一个更深入的了解小细胞肺癌的发生发展和测试了相当数量的新的和有针对性的药物,但目前的结果是弱或不足。迄今为止,小细胞肺癌仍然是研究人员面临的挑战。在这篇综述中,就小细胞肺癌的管理和标准和新的治疗方法的争议点的关键方面进行讨论。
关键词: 化疗,免疫治疗,管理,放射治疗,小细胞肺癌,靶向治疗。
图形摘要
Current Drug Targets
Title:Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Volume: 18 Issue: 3
Author(s): Giuseppe Lo Russo, Marianna Macerelli, Marco Platania, Nicoletta Zilembo, Milena Vitali, Diego Signorelli, Claudia Proto and Monica Ganzinelli, Rosaria Gallucci, Francesco Agustoni, Gianpiero Fasola, Filippo de Braud, Marina Chiara Garassino.
Affiliation:
关键词: 化疗,免疫治疗,管理,放射治疗,小细胞肺癌,靶向治疗。
摘要: Small cell lung cancer is a highly aggressive, difficult to treat neoplasm. Among all lung tumors, small cell lung cancers account for about 20%. Patients typically include heavy smokers in 70s age group, presenting with symptoms such as intrathoracic tumors growth, distant spread or paraneoplastic syndromes at the time of diagnosis. A useful and functional classification divides small cell lung cancers into limited disease and extensive disease. Concurrent chemo-radiotherapy is the standard treatment for limited disease, with improved survival when combined with prophylactic cranial irradiation. Platinum compounds (cisplatin/carboplatin) plus etoposide remain the cornerstone for extensive disease. Nevertheless, despite high chemo- and radio-sensitivity of this cancer, nearly all patients relapse within the first two years and the prognosis is extremely poor. A deeper understanding about small cell lung cancer carcinogenesis led to develop and test a considerable number of new and targeted agents but the results are currently weak or insufficient. To date, small cell lung cancer is still a challenge for researchers. In this review, key aspects of small cell lung cancer management and controversial points of standard and new treatments will be discussed.
Export Options
About this article
Cite this article as:
Giuseppe Lo Russo, Marianna Macerelli, Marco Platania, Nicoletta Zilembo, Milena Vitali, Diego Signorelli, Claudia Proto and Monica Ganzinelli, Rosaria Gallucci, Francesco Agustoni, Gianpiero Fasola, Filippo de Braud, Marina Chiara Garassino. , Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem, Current Drug Targets 2017; 18 (3) . https://dx.doi.org/10.2174/1389450117666160502152331
DOI https://dx.doi.org/10.2174/1389450117666160502152331 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
2-Deoxy-D-Ribose, a Downstream Mediator of Thymidine Phosphorylase, Regulates Tumor Angiogenesis and Progression
Anti-Cancer Agents in Medicinal Chemistry Treatment Approaches in Elderly Patients with Head and Neck Cancer
Anti-Cancer Agents in Medicinal Chemistry Potential Application of Gene Therapy to X-Linked Agammaglobulinemia
Current Gene Therapy Characterization of the Lymphotropic Amplicons-6 and Tamplicon-7 Vectors Derived from HHV-6 and HHV-7
Current Gene Therapy Smart Drug-Delivery Systems for Cancer Nanotherapy
Current Drug Targets Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism Controlled Releases of FGF-2 and Paclitaxel from Chitosan Hydrogels and their Subsequent Effects on Wound Repair, Angiogenesis, and Tumor Growth
Current Drug Delivery Synthesis and Biological Evaluation of 3,4-Dihydro-3-(3-methylisoxazol-5- yl)-2H-benzo[e][1,3]oxazine Derivatives as Anticancer Agents
Letters in Organic Chemistry Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Diagnostic Value of MiR-125b as a Potential Biomarker for Stage I Lung Adenocarcinoma
Current Molecular Medicine Advancement of Technology for Precision Medicine
Current Pharmaceutical Design Poly (Lactic-co-Glycolic Acid) & Tocopheryl Polyethylene Glycol Succinate Nanoparticles for the Treatment of Different Brain Cancers
Anti-Cancer Agents in Medicinal Chemistry Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF
Current Cancer Drug Targets Oncogenic MicroRNAs in the Genesis of Leukemia and Lymphoma
Current Pharmaceutical Design <i>Anastatica hierochuntica </i>Extracts: Promising, Safe and Selective Anticancer Agents
The Natural Products Journal Medicinal Chemistry of Antiviral/Anticancer Prodrugs Subjected to Phosphate Conjugation
Mini-Reviews in Medicinal Chemistry Use of the Semiconductor Nanotechnologies “Quantum Dots” for in vivo Cancer Imaging
Recent Patents on Anti-Cancer Drug Discovery CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety